Surgical Management of Recurrent Ovarian Cancer

Seminars in Oncology

Volumn 36, Issue 2, 2009, Pages 106-111

  Leitao Jr , Mario M ^a   Chi, Dennis S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DRUG RESPONSE; GASTROSTOMY; HUMAN; INTESTINE OBSTRUCTION; INTESTINE SURGERY; LAPAROSCOPY; OVARY CANCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECURRENT CANCER; SCORING SYSTEM; TREATMENT OUTCOME; TUMOR VOLUME;

FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PALLIATIVE CARE;

EID: 62949163716     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.12.002     Document Type: Article

References (43)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
3. Hoskins W.J. Surgical staging and cytoreductive surgery of epithelial ovarian cancer. Cancer 71 (1993) 1534-1540
4. Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol 103 (2006) 559-564
5. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
6. Tingulstad S., Skjeldestad F.E., and Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol 102 (2003) 499-505
7. Aletti G.D., Gostout B.S., Podratz K.C., and Cliby W.A. Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 100 (2006) 33-37
8. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Tobor M., and Fahey A. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98 (2006) 172-180
9. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 43
10. Norton L. Theoretical concepts and the emerging role of taxanes in adjuvant therapy. Oncologist 6 Suppl 3 (2001) 30-35
11. Goldie J.H., and Coldman J.A. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 3 (1979) 1727-1733
12. Bristow R.E., Puri I., and Chi D.S. Secondary cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol 108 (2008) S119
13. Berek J.S., Hacker N.F., Lagasse L.D., Nieberg R.K., and Elashoff R.M. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gyneol 61 (1983) 189-193
14. Segna R., Dottino P.R., Mandeli J.P.P., Konsker K., and Cohen C.J. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 11 (1993) 434-439
15. Lichtenegger W., Sehouli J., Buchmann E., Karajanev C., and Weidemann H. Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC). J Obstet Gynaecol Res 24 (1998) 447-451
16. Eisenkop S.M., Friedman R.L., and Spirtos N.M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 88 (2000) 144-153
17. Zang R.Y., Zhang Z.Y., Li Z.T., Chen J., Tang M.Q., Liu Q., et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 75 (2000) 24-30
18. Scarabelli C., Gallo A., and Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 83 (2001) 504-512
19. Zang R., Li Z.T., Zhang Z.Y., and Cai S.-M. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study. Int J Gynecol Cancer 13 (2003) 419-427
20. Zang R., Li Z.T., Tang J., Cheng X., Cai S.M., Zhang Z.Y., et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?. Cancer 100 (2004) 1152-1161
21. Ayhan A., Gultekin M., Taskiran C., Aksan G., Celik N.Y., Dursun P., et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol 194 (2006) 49-56
22. Chi D.S., McCaughty K., Diaz J.P., Huh J., Schwabenbauer S., Hummer A.J., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 (2006) 1933-1939
23. Harter P., du Bois A., Hahmann M., Burges A., Loibl S., Gropp M., et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13 (2006) 1702-1710
24. Salani R., Santillan A., Zahurak M.L., Giuntoli II R.L., Gardner G.J., and Armstrong D.K. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109 (2007) 685-691
25. Tebes S.J., Sayer R.A., Palmer J.M., Tebes C.C., Martino M.A., and Hoffman M.S. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 106 (2007) 482-487
26. Leitao Jr. M.M., Kardos S., Barakat R.R., and Chi D.S. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol 95 (2004) 181-188
27. Karam A.K., Santillan A., Bristow R.E., Giantoli II R., Gardner G.J., Cass I., et al. Tertiary cytoreductive surgery in recurrent ovarian cancer: selection criteria and survival outcome. Gynecol Oncol 104 (2007) 377-380
28. Bristow R.E., Duska L.R., Lambrou N.C., Fishman E.K., O'Neill M.J., Trimble E., et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89 (2000) 1532-1540
29. Funt S.A., Hricak H., Abu-Rustum N., Mazumdar M., Felderman H., and Chi D.S. Role of CT in the management of recurrent ovarian cancer. AJR Am J Roentgenol 182 (2004) 393-398
30. Sugarbaker P.H. Surgical oncology: contemporary principles and practice. In: Bland K., Daly J.M., and Karakousis C.P. (Eds). Management of peritoneal surface malignancy: appendix cancer and pseudomyxoma peritonei, colon cancer, gastric cancer, abdominopelvic sarcoma, and primary peritoneal malignancy (2001), McGraw-Hill, New York, NY 1149-1176
31. Helm C.W., Randall-Whitis L., Martin III R.S., Metzinger D.S., Gordinier M.E., Parker L.P., et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 105 (2007) 90-96
32. Cotte E., Glehen O., Mohammed F., Larny F., Falandry C., Golfier F., et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 31 (2007) 1813-1820
33. Meyn R.E., Corry P.M., Fletcher S.E., and Demetriades M. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminechloroplatinum(II). Cancer Res 40 (1980) 1136-1139
34. Alberts D.S., Peng Y.M., Chen H.S., Moon T.E., Cetas T.C., and Hoeschele J.D. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Cancer Inst 65 (1980) 455-461
35. Feuer D.J., Broadley K.E., Shepherd J.H., and Barton D.P. Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. Gynecol Oncol 75 (1999) 313-322
36. van Ooijen B., van der Burg M.E.L., Planting A.S.T., Siersema S.D., and Wiggers T. Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin. Surg Gynecol Obstet 176 (1993) 469-474
37. Ripamonti C., and Bruera E. Palliative management of malignant bowel obstruction. Int J Gynecol Cancer 12 (2002) 135-143
38. Winter III W.E., McBroom J.W., Carlson J.W., Rose G.S., and Elkas J.C. The utility of gastrojejunostomy in secondary cytoreduction and palliation of proximal intestinal obstruction in recurrent ovarian cancer. Gynecol Oncol 91 (2003) 261-264
39. Pothuri B., Vaidya A., Aghajanian C., Venkatraman E., Barakat R.R., and Chi D.S. Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol 89 (2003) 306-313
40. Mangili G., Aletti G., Frigerio L., Franchi M., Panacci N., Vigano R., et al. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer 15 (2005) 830-835
41. von Gruenigen V.E., Frasure H.E., Reidy A.M., and Gil K.M. Clinical disease course during the last year in ovarian cancer. Gynecol Oncol 90 (2003) 619-624
42. Pothuri B., Montemarano M., Gerardi M., Shike M., Ben-Porat L., Sabbatini P., et al. Percutaneous endoscopic gastrotomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol 96 (2005) 330-334
43. Brard L., Weitzen S., Strubel-Lagan S.L., Swamy N., Gorinier M.E., Moore R.G., et al. The effect of total parenteral nutrition on the survival of terminally ill ovarian cancer patients. Gynecol Oncol 103 (2006) 176-180